Evidence map›Paper›PMID 33551992›Full record

ArticleFrontiers in endocrinology2020

Case Report: Primary Hypothyroidism Associated With Lutetium 177-DOTATATE Therapy for Metastatic Paraganglioma.

Sriram Gubbi, Mohammad Al-Jundi, Jaydira Del Rivero, Abhishek Jha, Marianne Knue, Joy Zou, Baris Turkbey, Jorge Amilcar Carrasquillo, Emily Lin, Karel Pacak and 2 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in endocrinology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. New Biology of Pheochromocytoma and Paraganglioma.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Sriram GubbiMetabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, United States.
Mohammad Al-JundiDepartment of Endocrinology, Eunice Kennedy Shriver National Institute of Child and Human Development, National Institutes of Health, Bethesda, MD, United States.
Jaydira Del RiveroDevelopmental Therapeutics Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States.
Abhishek JhaDepartment of Endocrinology, Eunice Kennedy Shriver National Institute of Child and Human Development, National Institutes of Health, Bethesda, MD, United States.
Marianne KnueDepartment of Endocrinology, Eunice Kennedy Shriver National Institute of Child and Human Development, National Institutes of Health, Bethesda, MD, United States.
Joy ZouMolecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States.
Baris TurkbeyMolecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States.
Jorge Amilcar CarrasquilloDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
Emily LinDavis Senior High School, Davis, CA, United States.
Karel PacakDepartment of Endocrinology, Eunice Kennedy Shriver National Institute of Child and Human Development, National Institutes of Health, Bethesda, MD, United States.
Joanna Klubo-GwiezdzinskaMetabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, United States.
Frank I-Kai LinMolecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States.
National Cancer Institute · USNational Institutes of Health · USEunice Kennedy Shriver National Institute of Child Health and Human Development · USMemorial Sloan Kettering Cancer Center · USNational Institute of Diabetes and Digestive and Kidney Diseases · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Elisa de Stanchina · 1985 to 2026
$347.4M
Phase 2 study of Lu-177-DOTATATE in inoperable paraganglioma - pheochromocytoaZIABC011789 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI LIN, FRANK · 2017 to 2025
$1.9M
Intramural NIH HHS ZIA BC011789NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Background: Lutetium 177 ( Case Description: A 29-year-old male with Summary: We report, for the first time, a patient with asymptomatic primary hyperthyroidism who rapidly developed symptomatic primary hypothyroidism 1 month after Conclusions: Thyroid dysfunction can be associated with PRRT. Thyroid uptake patterns on pre-treatment diagnostic somatostatin analog scans might predict individual susceptibility to PRRT-associated TFT disruption. Therefore, periodic evaluation of TFTs should be considered in patients receiving PRRT.

Indexed as

HypothyroidismOctreotideOrganometallic CompoundsParagangliomaRadiopharmaceuticalsAdultAsymptomatic DiseasesClinical Trials as TopicHashimoto DiseaseHumansMaleNeoplasm MetastasisPositron Emission Tomography Computed TomographySuccinate DehydrogenaseThyroid GlandThyroxinegallium Ga 68 dotatatelutetium Lu 177 dotatateOctreotideOrganometallic CompoundsRadiopharmaceuticalsSDHB protein, humanSuccinate DehydrogenaseThyroxineDOTATATEhypothyroidismLutatheraparagangliomapeptide receptor radionuclide therapy

Identifiers

PMID33551992
PMCPMC7859638
OpenAlexW3121476345

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.